Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Utilizing Micro-RNA-371a-3p for Recurrence Prediction in Clinical Stage I Testicular Cancer.

The oncologist·2026
Same author

Stereotactic radiosurgery and multimodal integration approaches for germ cell tumor brain relapse.

Journal of neuro-oncology·2026
Same author

Real-World Evidence of Treatment Patterns, Time to Real-World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States.

Cancer medicine·2026
Same author

How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study.

EClinicalMedicine·2026
Same author

Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

相关实验视频

Updated: Jun 24, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.4K

在基斯普拉丁基化疗后进行全面的听力学分析.

Victoria A Sanchez1, Paul C Dinh2, Patrick O Monahan3

  • 1Department of Otolaryngology-Head and Neck Surgery, University of South Florida, Tampa.

JAMA oncology
|June 6, 2024
PubMed
概括

与西斯相关的听力损失 (CRHL) 在癌症幸存者中很常见,进展与累积剂量和高胆固醇血症有关. 定期听力学评估和高胆固醇血症管理对于幸存者的听力管理至关重要.

更多相关视频

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

19.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

相关实验视频

Last Updated: Jun 24, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.4K
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

19.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

科学领域:

  • 耳毒性和听力学
  • 癌症的生存率 癌症的生存率
  • 长度健康结果的长度

背景情况:

  • 西斯是一种广泛使用的化疗剂,因其耳毒性而闻名.
  • 在使用综合性听力学评估的成年癌症幸存者中,关于西斯普拉丁相关听力损失 (CRHL) 进展的数据有限.
  • 了解风险因素和纵向变化对于管理这一群体的听力健康至关重要.

研究的目的:

  • 通过使用包括Word-in-Noise (WIN) 在内的综合性听力测试来评估CRHL.
  • 为了评估CRHL的纵向进展.
  • 确定与CRHL及其进展相关的风险因素.

主要方法:

  • 一项对100名接受西斯丁治疗的丸癌幸存者 (TCS) 的纵向研究,并进行持续的随访.
  • 综合性听力学评估,包括全频谱听力测量和WIN测试.
  • 多变量分析以确定与听力损失及其进展相关的因素.

主要成果:

  • 78%的TCS在随访时显示有声度学定义的听力损失,自我报告的听力损失与更糟糕的结果相关.
  • 较差的WIN表现与高胆固醇血症,低教育和听力损失严重程度有关.
  • CRHL进展与高胆固醇血症和年龄增加有关,与累积思普拉丁剂量 (>300 mg/m2) 有显著的相互作用.

结论:

  • 对于接受西斯丁治疗的幸存者来说,建议严格控制高胆固醇血症和定期进行听力学评估.
  • 风险分层应纳入听力问题.
  • CRHL的进展与累积的西斯普拉丁剂量有关,这需要进一步的长期研究.